Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease | springermedizin.de

Springer Medizin

nach oben

Current Cardiology Reports

Erschienen in:

01.05.2015 | Interventional Cardiology (S Rao, Section Editor)

Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease

verfasst von: Subhash Banerjee, Karan Sarode, Atif Mohammad, Emmanouil S. Brilakis

Erschienen in: Current Cardiology Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Endovascular management of superficial femoral artery disease has historically been limited to percutaneous balloon angioplasty, atherectomy, and bare-metal stents. However, these therapies have been plagued by high restenosis and target lesion revascularization rates. More recent technologies such as drug-coated stents and balloons are designed to combat restenosis by locally delivering antiproliferative drugs. Several randomized controlled trials have directly compared these antiproliferative drug-delivering devices to their non-drug-coated counterparts. Additionally, trials are currently ongoing to compare use of drug-coated technologies in combination with traditional therapies in hope of synergistic effects. This review gathers data from currently published clinical trials, provides an overview of upcoming clinical studies utilizing drug-coated technology, and explores the possible impact these devices may have on clinical practice.

Anzeige

1.

Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–43.CrossRefPubMed

2.

Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317–24.CrossRefPubMed

3.

Wood NB, Zhao SZ, Zambanini A, et al. Curvature and tortuosity of the superficial femoral artery: a possible risk factor for peripheral arterial disease. J Appl Physiol. 2006;101:1412–8.CrossRefPubMed

4.

Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991;20:384–92.CrossRefPubMed

5.

Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation. 1991;83:I70–80.CrossRefPubMed

6.

Nadal LL, Cynamon J, Lipsitz EC, Bolia A. Subintimal angioplasty for chronic arterial occlusions. Tech Vasc Interv Radiol. 2004;7:16–22.CrossRefPubMed

7.

Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3:229–34.CrossRefPubMedCentralPubMed

8.

Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. New Engl J Med. 2006;354:1879–88.CrossRefPubMed

9.

Dick P, Wallner H, Sabeti S, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Cath Cardiovasc Interv. 2009;74:1090–5.CrossRef

10.

Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–76.CrossRefPubMed

11.

Chalmers N, Walker PT, Belli AM, et al. Randomized trial of the SMART stent versus balloon angioplasty in long superficial femoral artery lesions: the SUPER study. Cardiovasc Intervent Radiol. 2013;36:353–61.CrossRefPubMed

12.

Lepantalo M, Laurila K, Roth WD, et al. PTFE bypass or thrupass for superficial femoral artery occlusion? A randomised controlled trial. Eur J Vasc Endovasc. 2009;37:578–84.CrossRef

13.

Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48:1573–8.CrossRefPubMed

14.

Banerjee S, Pershwitz G, Sarode K, et al. Stent and non-stent based outcomes of infrainguinal peripheral artery interventions from the multicenter XLPAD registry. J Inv Cardiol 2014.

15.••

Sarode K, Spelber DA, Bhatt DL, et al. Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. JACC Cardiovasc Interv. 2014;7:827–39. This review provides a thorough description of studies utilizing drug delivering technologies in femoropopliteal and below-the-knee arteries.CrossRefPubMed

16.

Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852–5.CrossRefPubMed

17.

Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188–93.CrossRefPubMed

18.

Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636–45.CrossRefPubMed

19.

Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circulation Res. 2000;86:879–84.CrossRefPubMed

20.

Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–10.CrossRefPubMed

21.

Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394–401.CrossRefPubMed

22.•

Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–27. This study provides data from a multicenter randomized controlled trial comparing drug coated stents to percutaneous transluminal angioplasty and provisional bare metal stenting. Also included are results from a large sample single-arm trial which incorporates increased disease and lesion severity.CrossRefPubMed

23.

The proven effect of Zilver PTX at 4 years. Available at https://www.cookmedical.com/data/resources/clinicalReferences/PI-NAM-11371-EN-201312-M3.pdf. Accessed November 26, 2014.

24.

Yokoi H. Zilver PTX Japan PMS. Presented at Vascular Interventional Advances Scientific Sessions. Las Vegas. 2014.

25.

Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–65.CrossRefPubMed

26.

Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. New Engl J Med. 2008;358:689–99.CrossRefPubMed

27.

Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–40.CrossRefPubMed

28.

Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–9.CrossRefPubMed

29.

Schienert D. Biolux P-I: First in-human randomized controlled trial of Passeo-18 Lux DRB vs. POBA in femoropopliteal arteries: 12 month results. Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Sessions. San Francisco. 2013.

30.

Liistro F, Angioli P, Porto I, et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014;21:1–8.CrossRefPubMed

31.

Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295–302.CrossRefPubMed

32.

Karimi A, de Boer SW, van den Heuvel DA, et al. Randomized trial of Legflow® paclitaxel eluting balloon and stenting versus standard percutaneous transluminal angioplasty and stenting for the treatment of intermediate and long lesions of the superficial femoral artery (RAPID trial): study protocol for a randomized controlled trial. Trials. 2013;14:87.CrossRefPubMedCentralPubMed

33.

Tacke J. TCT-268 Randomized clinical trial favors the use of drug-coated balloons over plain balloons for the postdilatation of nitinol stents in the SFA and PI segment to lower restenosis rate. Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Sessions. Washington, DC. 2014.

34.

Zeller T. DEFINITIVE-AR 12-month results: directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency. Presented at Vascular Interventional Advances (VIVA) Scientific Sessions. Las Vegas. 2014.

35.

Sixt S, Carpio Cancino OG, Treszl A, et al. Drug-coated balloon angioplasty after directional atherectomy improves outcome in restenotic femoropopliteal arteries. J Vasc Surg. 2013;58:682–6.CrossRefPubMed

36.

Kearns BC, Michaels JA, Stevenson MD, Thomas SM. Cost-effectiveness analysis of enhancements to angioplasty for infrainguinal arterial disease. Br J Surg. 2013;100:1180–8.CrossRefPubMed

37.

Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery: successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J. 2003;24:1462–7.CrossRefPubMed

38.

Sarode K. TCT-523 Multicenter Registry for Peripheral Arterial Disease Interventions and Outcomes (XLPAD Registry). Presented at Transcatheter Cardiovascular Therapeutics (TCT) Scientific Sessions. San Francisco. 2013.

39.

Safian R, Freed, MS. Manual of interventional cardiology, Abridged. 3rd Edition ed: Jones & Bartlett Learning. 2001.

40.

Fanelli F, Cannavale A, Boatta E, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endvoasc Ther. 2012;19:571–80.CrossRef

41.

Rosenfield K. 12-month LEVANT 2 results. Presented at Vascular Interventional Advances (VIVA) Scientific Sessions. Las Vegas. 2014.

42.

Evaluation of paclitaxel eluting stent vs. paclitaxel eluting balloon treating peripheral artery disease of the femoral artery. Available at http://clinicaltrials.gov/ct2/show/NCT01728441.

Titel: Drug-Coated Balloon and Stent Therapies for Endovascular Treatment of Atherosclerotic Superficial Femoral Artery Disease
verfasst von: Subhash Banerjee
Karan Sarode
Atif Mohammad
Emmanouil S. Brilakis
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Current Cardiology Reports / Ausgabe 5/2015
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-015-0586-8

Anzeige

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen